Amicus Therapeutics Revenue 2007-2021 | FOLD

Amicus Therapeutics revenue from 2007 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Amicus Therapeutics Annual Revenue
(Millions of US $)
2020 $261
2019 $182
2018 $91
2017 $37
2016 $5
2015 $
2014 $1
2013 $0
2012 $18
2011 $21
2010 $1
2009 $64
2008 $15
2007 $2
2006 $2
2005 $
Amicus Therapeutics Quarterly Revenue
(Millions of US $)
2021-09-30 $80
2021-06-30 $77
2021-03-31 $66
2020-12-31 $71
2020-09-30 $67
2020-06-30 $62
2020-03-31 $61
2019-12-31 $55
2019-09-30 $49
2019-06-30 $44
2019-03-31 $34
2018-12-31 $33
2018-09-30 $21
2018-06-30 $21
2018-03-31 $17
2017-12-31 $15
2017-09-30 $11
2017-06-30 $7
2017-03-31 $4
2016-12-31 $3
2016-09-30 $2
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30
2013-03-31
2012-12-31 $0
2012-09-30
2012-06-30 $11
2012-03-31 $8
2011-12-31 $6
2011-09-30 $6
2011-06-30 $4
2011-03-31 $6
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31 $49
2009-09-30 $5
2009-06-30 $5
2009-03-31 $5
2008-12-31 $4
2008-09-30 $4
2008-06-30 $4
2008-03-31 $3
2007-12-31
2007-09-30
2007-06-30
2007-03-31
2006-09-30
2006-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.566B $0.261B
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00